Compare Godaddy Inc (GDDY) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Godaddy Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Godaddy Inc trades at $103.99 (market cap $13.05B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Godaddy Inc is far larger — about 13.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Godaddy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Godaddy Inc for 65 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| GDDY | MRVI | |
|---|---|---|
Market Cap | $13.05B | $972.90M |
Volume | 1,123,303 | 4,325,710 |
Sector | Technology | Health |
52-Week High | $135.18 | $9.00 |
52-Week Low | $75.07 | $2.83 |
Typical Hold Time | 65 Days | 0 Days |
Enterprise Value | $15.73B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoDaddy (GDDY) trades at $103.36, up 1.02% today, with a bullish technical signal from moving averages. The company reported revenue of $4.95B in 2025 and net income of $875M, with consistent earnings beats in recent quarters. However, the stock faces headwinds from a securities class action lawsuit alleging misrepresentations about domain contract terms, as reported by multiple law firms in late September 2026.
The outlook is mixed: strong profitability and earnings momentum support upside, but legal risks and a consensus price target below the current price suggest caution. Investors should weigh robust fundamentals against litigation overhangs and monitor Q3 2026 earnings for further direction.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
